South Korea’s two leading biopharmaceutical companies, Samsung Biologics and Celltrion, unveiled ambitious plans to enter the ...

In patients with high-risk HER2-positive breast cancer, post-surgery, or adjuvant, treatment with trastuzumab emtansine ...

Topline results from the Chinese portion of the trial for the antibody-drug conjugate (ADC) TIVDAK support the company’s regulatory plans.

Korea’s top biopharmaceutical firms, Celltrion and Samsung Biologics, envisioned their future strategies for expansion at J.P ...